Resources

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 7 of this Exclusive Interview, Dr. Mechanick shares his thoughts on what healthcare professionals should do to affect change in government legislation.

In this week's Homerun Slides: EMPA-REG Outcome Trial Part 1: Meta-analysis of intensive glucose control in T2DM.

Central nervous effects: A role for GLP-1 in the central nervous regulation of food intake has been inferred from the high density of GLP-1 receptors in the hypothalamus. Also, direct intracerebroventricular administration of GLP-1 has caused a significant reduction in food intake in rats, and these actions could be abolished by co-administration of the GLP-1 receptor antagonist exendin.

IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.

Therapy shows neutral CV benefit, increases bleeding risk in type 2 diabetes.

Study finds treatment on top of stable renin angiotensin system (RAS)-inhibition decreased risk.

Study shows death rate more than five times higher than in those without the disease.

Organizations publish recommendations for identifying and reporting hypoglycemia in clinical studies.

Transcript: Dr. Richard Bergenstal, endocrinologist and an executive director of the International Diabetes Center at Park Nicollet, discusses hybrid closed-loop technology.

Video: Diabetes in Control Publisher Steve Freed talks with Dr. Richard Bergenstal about his work on the hybrid closed-loop system, the first of its kind to be awarded approval by the FDA.